Real-world data analysis of patients with cancer of unknown primary

Abstract Cancer of unknown primary (CUP) is a heterogeneous malignancy in which the primary site of the tumor cannot be identified through standard work-up. The survival outcome of CUP is generally poor, and there is no consensus for treatment. Here, we comprehensively analyzed the real-world data o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sora Kang, Jae Ho Jeong, Shinkyo Yoon, Changhoon Yoo, Kyu-pyo Kim, Hyungwoo Cho, Baek-Yeol Ryoo, Jinhong Jung, Jeong Eun Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8d52adec9532400fb509dd2322c3ccfb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d52adec9532400fb509dd2322c3ccfb
record_format	dspace
spelling	oai:doaj.org-article:8d52adec9532400fb509dd2322c3ccfb2021-12-05T12:12:18ZReal-world data analysis of patients with cancer of unknown primary10.1038/s41598-021-02543-12045-2322https://doaj.org/article/8d52adec9532400fb509dd2322c3ccfb2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02543-1https://doaj.org/toc/2045-2322Abstract Cancer of unknown primary (CUP) is a heterogeneous malignancy in which the primary site of the tumor cannot be identified through standard work-up. The survival outcome of CUP is generally poor, and there is no consensus for treatment. Here, we comprehensively analyzed the real-world data of 218 patients with CUP (median age, 62 years [range, 19–91]; male, 62.3%). Next-generation sequencing was conducted in 22 (10%) patients, one of whom showed level 1 genetic alteration. Most (60.3%) patients were treated with empirical cytotoxic chemotherapy, and two patients received targeted therapy based on the NGS results. The median OS was 8.3 months (95% confidence interval [CI] 6.2–11.4), and the median progression-free survival of patients treated with chemotherapy was 4.4 months (95% CI 3.4–5.3). In multivariate Cox regression analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 and localized disease were significantly associated with favorable survival outcomes. Collectively, we found that CUP patients had a poor prognosis after standard treatment, and those with localized disease who received local treatment and those with better PS treated with multiple lines of chemotherapy had better survival outcomes. Targeted therapies based on NGS results are expected to improve survival outcomes.Sora KangJae Ho JeongShinkyo YoonChanghoon YooKyu-pyo KimHyungwoo ChoBaek-Yeol RyooJinhong JungJeong Eun KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sora Kang Jae Ho Jeong Shinkyo Yoon Changhoon Yoo Kyu-pyo Kim Hyungwoo Cho Baek-Yeol Ryoo Jinhong Jung Jeong Eun Kim Real-world data analysis of patients with cancer of unknown primary
description	Abstract Cancer of unknown primary (CUP) is a heterogeneous malignancy in which the primary site of the tumor cannot be identified through standard work-up. The survival outcome of CUP is generally poor, and there is no consensus for treatment. Here, we comprehensively analyzed the real-world data of 218 patients with CUP (median age, 62 years [range, 19–91]; male, 62.3%). Next-generation sequencing was conducted in 22 (10%) patients, one of whom showed level 1 genetic alteration. Most (60.3%) patients were treated with empirical cytotoxic chemotherapy, and two patients received targeted therapy based on the NGS results. The median OS was 8.3 months (95% confidence interval [CI] 6.2–11.4), and the median progression-free survival of patients treated with chemotherapy was 4.4 months (95% CI 3.4–5.3). In multivariate Cox regression analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 and localized disease were significantly associated with favorable survival outcomes. Collectively, we found that CUP patients had a poor prognosis after standard treatment, and those with localized disease who received local treatment and those with better PS treated with multiple lines of chemotherapy had better survival outcomes. Targeted therapies based on NGS results are expected to improve survival outcomes.
format	article
author	Sora Kang Jae Ho Jeong Shinkyo Yoon Changhoon Yoo Kyu-pyo Kim Hyungwoo Cho Baek-Yeol Ryoo Jinhong Jung Jeong Eun Kim
author_facet	Sora Kang Jae Ho Jeong Shinkyo Yoon Changhoon Yoo Kyu-pyo Kim Hyungwoo Cho Baek-Yeol Ryoo Jinhong Jung Jeong Eun Kim
author_sort	Sora Kang
title	Real-world data analysis of patients with cancer of unknown primary
title_short	Real-world data analysis of patients with cancer of unknown primary
title_full	Real-world data analysis of patients with cancer of unknown primary
title_fullStr	Real-world data analysis of patients with cancer of unknown primary
title_full_unstemmed	Real-world data analysis of patients with cancer of unknown primary
title_sort	real-world data analysis of patients with cancer of unknown primary
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8d52adec9532400fb509dd2322c3ccfb
work_keys_str_mv	AT sorakang realworlddataanalysisofpatientswithcancerofunknownprimary AT jaehojeong realworlddataanalysisofpatientswithcancerofunknownprimary AT shinkyoyoon realworlddataanalysisofpatientswithcancerofunknownprimary AT changhoonyoo realworlddataanalysisofpatientswithcancerofunknownprimary AT kyupyokim realworlddataanalysisofpatientswithcancerofunknownprimary AT hyungwoocho realworlddataanalysisofpatientswithcancerofunknownprimary AT baekyeolryoo realworlddataanalysisofpatientswithcancerofunknownprimary AT jinhongjung realworlddataanalysisofpatientswithcancerofunknownprimary AT jeongeunkim realworlddataanalysisofpatientswithcancerofunknownprimary
_version_	1718372142883536896

Real-world data analysis of patients with cancer of unknown primary

Ejemplares similares